MAPT and Mental deterioration: Specifically, compared with noncarriers, APOE4 carriers had annual rates of cognitive decline per 1–log10 unit higher levels in t-tau and GFAP that were accelerated by a β (SD) of −0.03 (0.02) (P = .046) and −0.07 (0.03) (P = .02), respectively.